Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$0.86+8.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · CTOR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive commercial adoption and revenue growth of LYMPHIR through expanding institutional demand, formulary inclusion, and sales force deployment.
Stated as a priority in 2 of last 2 quarters. Revenue from LYMPHIR sales totaled $7.1 million for the first nine months of fiscal 2026, with $1.7 million in Q1 and $1.5 million in Q2. Institutional vial orders increased 31% sequentially from 708 to 926 in Q3 2026, with 44 institutions prescribing LYMPHIR and 83% of target accounts on formulary or in review in Q1. The commercial team expanded to nationwide coverage by Q3. The trajectory shows delivering growth in institutional adoption and revenue.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Institutional vial orders grew 31% sequentially, from 708 to 926 in Q3 2026; 44 institutions have prescribed LYMPHIR.”
“83% of target accounts have added or are progressing LYMPHIR through formulary review; expecting full commercial team by mid-summer.”
Secure financing and manage debt and equity capital to support LYMPHIR commercialization and maintain liquidity.
Stated as a priority in 2 of last 2 quarters. The company secured up to $36.5 million in combined debt and equity financing in May 2026, including a $25 million senior secured term loan and $11.5 million from warrant exercises. Cash and cash equivalents increased from $2.6 million at Q1 end to $16.6 million at Q2 end. Management is delivering enhanced financial flexibility to support commercialization and working capital.
“Received approximately $9.7 million from warrant exercises and funded $10 million under a senior secured term loan facility.”
“Secured up to $36.5 million in combined financing including a $25 million senior secured term loan facility and $11.5 million from warrant exercises.”
Support investigator-initiated Phase 1 studies of LYMPHIR combined with pembrolizumab and CAR-T therapy to explore broader oncology indications.
Stated as a priority in 2 of last 2 quarters. Management highlighted investigator-initiated Phase 1 studies showing a 24% overall response rate and 20.5 months median progression-free survival for LYMPHIR plus pembrolizumab in gynecologic cancers, and an 86% overall response rate including 57% complete response for LYMPHIR prior to CAR-T therapy in lymphoma. The trajectory shows delivering clinical development progress.
“Advanced two investigator-initiated Phase 1 studies of LYMPHIR in combination settings, including pembrolizumab and CAR-T therapy.”
“Announced positive topline results from Phase 1 studies evaluating LYMPHIR with pembrolizumab and prior to CAR-T therapy.”
Build and deploy a nationwide commercial and medical affairs team to accelerate LYMPHIR adoption and support broader market access.
Stated as a priority in 2 of last 2 quarters. The commercial organization expanded from an initial field sales team in Q1 2026 to a 29-person nationwide commercial and medical affairs team by Q3 2026. This buildout supports accelerating commercial execution and broader adoption of LYMPHIR. The trajectory shows delivering expansion of commercial infrastructure.
“Expanded commercial organization by 21 field-based professionals and added eight medical science liaisons.”
“Recruited and trained initial field sales team, with expanded recruitment underway; full commercial team expected by mid-summer.”
Regain compliance with Nasdaq continued listing standards to maintain stock exchange listing.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.